ZP
REPL icon

Zimmer Partners’s Replimune Group REPL Stock Holding History

Zimmer Partners’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-20,000
Closed -$322K – 97
2018
Q3 		$322K Buy
+20,000
New +$351K ﹤0.01% 93

Other funds holding REPL

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Zimmer Partners's REPL Position: Q4 2018 in Review

Zimmer Partners sold out of Replimune Group (REPL) in Q4 2018, closing a stake of 20,000 shares — an estimated $322K sold.

Zimmer Partners first reported a position in REPL in Q3 2018 and held it in 1 quarter. The position peaked at $322K in Q3 2018. 51 funds tracked by Wall St. Rank hold REPL as of Q4 2018.

  • Zimmer Partners reported no remaining Replimune Group position as of Q4 2018 after selling out during the quarter.
  • Zimmer Partners sold 20,000 Replimune Group shares in Q4 2018, an estimated $322K.
  • Zimmer Partners first reported a position in Replimune Group in Q3 2018 and held it in 1 quarter.
  • Zimmer Partners's Replimune Group position peaked at $322K in Q3 2018.
  • 51 funds tracked by Wall St. Rank held Replimune Group as of Q4 2018.

Based on Zimmer Partners's 13F filing for Q4 2018, filed 14 Feb 2019.